ML21158A070: Difference between revisions

From kanterella
Jump to navigation Jump to search
(StriderTol Bot change)
(StriderTol Bot change)
Line 18: Line 18:


=Text=
=Text=
{{#Wiki_filter:June 8, 2021 Dr. Gregory Piefer, Chief Executive Officer SHINE Medical Technologies, LLC 101 East Milwaukee Street, Suite 600 Janesville, WI 53545
{{#Wiki_filter:}}
 
==SUBJECT:==
SHINE MEDICAL TECHNOLOGIES, LLC - ACCEPTANCE OF THE APPLICATION FOR A CONSTRUCTION PERMIT AMENDMENT RELATED TO THE RECEIPT AND POSSESSION OF CERTAIN RADIOACTIVE MATERIALS (EPID NO. L-2021-LLA-0104)
 
==Dear Dr. Piefer:==
 
By {{letter dated|date=April 29, 2021|text=letter dated April 29, 2021}} (Agencywide Documents Access and Management System Accession No. ML21119A166), SHINE Medical Technologies, LLC (SHINE) applied for an amendment to Construction Permit No. CPMIF-001 for its Medical Isotope Production Facility.
The license amendment request (LAR) proposes to receive and possess certain radioactive materials necessary for the continued construction of the SHINE Medical Isotope Production Facility. Consistent with Title 10 of the Code of Federal Regulations (10 CFR) 50.90, Application for amendment of license, construction permit, or early site permit, an application to amend the construction permit must fully describe the changes desired and follow, as far as applicable, the form prescribed for original applications. The requirements in 10 CFR 50.34, Contents of applications; technical information, cover the technical information to be included in the application and stipulate that it address design and operating characteristics, unusual or novel design features, and principal safety considerations.
The U.S. Nuclear Regulatory Commission (NRC) staff performed an acceptance review of the LAR and concluded that it includes sufficient information for the NRC staff to begin its detailed technical review. Notwithstanding the acceptance review, the NRC staff may require additional information to complete the detailed technical review. If needed, the NRC staff will request this information by separate correspondence within approximately 30 days of the date of this letter.
Based on the acceptance review, the NRC staff expects to complete its review and make a final determination on the LAR by August 31, 2021. This date could change due to several factors, including requests for additional information, unanticipated changes to the scope of the review, unsolicited supplements to the LAR, and others. If the forecasted date changes, the NRC staff will notify SHINE in writing of the new date and an explanation of the reason for the change.
 
G. Piefer                                    If you or other SHINE representatives have any questions, please contact me at (301) 415-1524, or by electronic mail at Steven.Lynch@nrc.gov.
Sincerely, Signed by Lynch, Steven on 06/08/21 Steven T. Lynch, Senior Project Manager Non-Power Production and Utilization Facility Licensing Branch Division of Advanced Reactors and Non-Power Production and Utilization Facilities Office of Nuclear Reactor Regulation cc: See next page
 
SHINE Medical Technologies, LLC            Docket No. 50-608 cc:
Jeff Bartelme Licensing Manager SHINE Medical Technologies, LLC 101 East Milwaukee Street, Suite 600 Janesville, WI 53545 Nathan Schleifer General Counsel SHINE Medical Technologies, LLC 101 East Milwaukee Street, Suite 600 Janesville, WI 53545 Christopher Landers Director, Office of Conversion National Nuclear Security Administration, NA 23 U.S. Department of Energy 1000 Independence Avenue, SW Washington, DC 20585 Mark Paulson Supervisor Radiation Protection Section Wisconsin Department of Health Services P.O. Box 2659 Madison, WI 53701-2659 Test, Research and Training Reactor Newsletter Attention: Amber Johnson Dept. of Materials Science and Engineering University of Maryland 4418 Stadium Drive College Park, MD 20742-2115 Mark Freitag City Manager P.O. Box 5005 Janesville, WI 53547-5005 Bill McCoy 1326 Putnam Avenue Janesville, WI 53546 Alfred Lembrich 541 Miller Avenue Janesville, WI 53548
 
ML21158A070                                        NRR-106 OFFICE                NRR/DANU/PM          NRR/DANU/LA      RIII/DNMS/BC NAME                  SLynch                NParker          ROrlikowski DATE                  6/7/2021              6/7/2021        6/7/2021 OFFICE                NMSS/REFS/BC          NRR/DANU/BC      NRR/DANU/PM NAME                  RElliott              JBorromeo        SLynch DATE                  6/7/2021              6/8/2021        6/8/2021}}

Revision as of 09:26, 8 September 2021

Shine Medical Technologies, LLC - Acceptance of the Application for a Construction Permit Amendment Related to the Receipt and Possession of Certain Radioactive Materials
ML21158A070
Person / Time
Site: SHINE Medical Technologies
Issue date: 06/08/2021
From: Steven Lynch
NRC/NRR/DANU/UNPL
To: Piefer G
SHINE Medical Technologies
Lynch S
References
EPID L-2021-LLA-0104
Download: ML21158A070 (4)
v • d • e


Text

Retrieved from "https://kanterella.com/w/index.php?title=ML21158A070&oldid=3281667"